Our vision

Where technology meets healthcare

About us

Our mission

Our goal is to vastly improve patient care and outcomes by bringing innovative eyecare technology to the healthcare industry. We want to significantly advance the efficacy and safety of existing eyecare drugs, while developing new ophthalmic drugs that address many unmet medical needs.

Through our unique and extensive partnerships, we are able to identify and launch new technologies into beneficial treatments that can help many patients worldwide.

our Product pipeline

IC265 Potent syk kinase inhibitor

  • Phase II Proof of Concept completed Q1 2018 using conjunctival allergen challenge model
  • Positive anti-inflammatory activity demonstrated with impressive effects on hyperemia v. olopatadine (antihistamine) and prednisolone (steroid)
  • Ready for Phase II study in dry eye
  • The global dye eye disease market is projected to rise from US$ 5.0B in 2016 to US$ 7.8B by 2025

IC702 Broad-spectrum ocular antibiotic

  • Greater potential potency compared to currently marketed ocular antibiotics, including the isolates of greatest concern to Opthalmologists: fluoroquinolone-resistant, and multi-drug resistant clinical isolates including methicillinresistant staphylococcus aureus (MRSA)
  • Extensive GLP systemic toxicology package is completed
  • Formulation work underway with rapid deployment into Phase II expected

IC133 Topical cyclosporine for dry eye

  • Next-generation topical cyclosporine with advanced nano-encapsulation drug delivery technology
  • Potential for up to 10 times the cyclosporine delivery in ocular tissues than Restasis®, the market leader
  • Target product profile: Once a day dosing; Less viscosity; Better tolerability; Faster onset; Better efficacy; Surfactant free

With a resolute emphasis on knowledge-based innovation, proven skills of individuals and unique partnerships, I think we are witnessing a new era in ophthalmic drug delivery.

Orest Olejnik

Chief Scientific Officer

steps to success and milestones

Invest in our Future

We are currently exploring partnerships and development opportunities that would support the development and commercialization of our pipeline products.

acquired technology

We acquired rights to develop and commercialize IC133 in 2017. We acquired rights to IC702 and IC265 in 2019.

Begin Clinical trials

IC265 is entering Phase II clinical trials. IC702 and IC133 are being developed and prepared for an IND.

Completed in 2017

Currently pursuing

on the horizon

The IACTA team

Cultivating IACTA's vision with leadership, experience, and insight


Damon Burrows

Founder / Chief Executive Officer

Damon is an experienced Pharmaceutical Executive with 20 years experience working in the life sciences and healthcare industries. He has experience in large and small pharmaceutical companies and has successfully navigated numerous drug development programs through the FDA regulatory approval process and commercial launch. He has extensive Public Policy experience and has worked with numerous Federal and State Agencies on the Regulatory challenges of commercialization.

Stephen Johnson, Hon BSC, MBA

Chief Operating Officer

Steve has 30+ years of demonstrated success in the pharmaceutical/biotech and medical device industries. He has held various executive leadership and management positions within R&D and has lead numerous global Rx, OTC, and device projects.

Prior to joining IACTA, Steve provided his expertise to pharmaceutical and device companies as a Management Consultant. He used is cumulated knowledge of portfolio management, project management, strategic planning, clinical operations, IT, QC/QA, biostatistics, and data management to help develop a number of new technologies.

Steve has also held various executive positions at Allergan Inc. for over 18 years. He served as a member of the R&D executive governance committees whose responsibilities included the successful development and global registration of key products, as well as the oversight of projects, budgets, facilities, human capital, and R&D productivity.

Steve has a Masters in Business Administration from the University of Missouri and an Honors Degree in Biochemistry and Pharmacology from the University of Western Ontario.

Orest Olejnik, PhD, FRPharmS

Chief Scientific Officer

Orest has more than 35 years of product development experience, covering both small and large molecules, including novel ocular drug delivery systems, within the pharmaceutical industry. Prior to joining IACTA, Orest was the Senior Vice President of Global Pharmaceutical Sciences at Allergan, Inc. He also held positions at Johnson & Johnson, CooperVision, and Fisons.

Orest has contributed to well over 30 regulatory submissions, representing a successfully strong track record for product approvals worldwide, with a predominant emphasis in ophthalmology. He was also a pivotal contributor and inventor covering numerous marketed products including those used in the treatment of glaucoma and dry eye.

Orest is a fellow of the Royal Pharmaceutical Society of Great Britain. He received his Ph.D. from the University of Nottingham, UK and his B.Sc. (Hons) in Pharmacy from the Sunderland School of Pharmacy, UK.

He has held academic positions, most recently as visiting professor at the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Scotland.

William Pedranti, JD

Chief Administrative Officer

Will is Chief Administrative Officer for IACTA.  He is a biotech entrepreneur who has co-founded several biotech companies; one of which was sold for $70 million. Will was most recently the President, Operations for Scilex Pharmaceuticals, a company which he co-founded and recently received approval for and launched a prescription non-opioid drug for the treatment of pain. Will's past experience includes working as a partner at national law firms as well as the Vice President, General Counsel and member of the Executive Committee of a publicly traded, commercial-stage biotech company that operated globally. Will has experience with oversight of all operations of a company, including commercial, R&D, finance, manufacturing, corporate governance, legal, compliance, regulatory, business development, international operations, litigation/disputes, securities and intellectual property functions.

Len Brandt

Strategic Advisor

Len, a venture capital veteran from Norwest VP, founding CEO for CNS Response, and a leading strategist for numerous medical ventures, brings over 30 years of experience in successfully commercializing health innovations. Many of these companies have provided industry firsts including, Platelet-rich Plama (PRP) in wound healing (Curatech), liposomes drug delivery (Liposome Technology Inc.), rational drug design and structural biology (Vertex), saphenous vein harvesting for bypass (Embro Vascular), deep brain stimulation (Micronet Medical/ Advanced Neuromodulation Systems), and predictive analytics in medication management (CNS Response). Most recently, Len has seen success in aesthetics neuro-toxin innovation through the 2014 founding and 2018 sale of Bonti, Inc. to Allergan.

IACTA In the news

View our Awards, recognitions, and Press releases

Read more